Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

• José Trigo ^[5] ; Mónica García-Cosío ^[1] ; Almudena García-Castaño ^[2] ; Montserrat Gomà ^[6] ; Ricard Mesia-Nin ^[7] ; Elena Ruiz-Bravo ^[3] ; Ainara Soria-Rivas ^[1] ; Paola Castillo ^[4] ; Irene Braña-García ^[8] ; Margarita Alberola-Ferranti ^[9]
  1. [1] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  2. [2] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  3. [3] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  4. [4] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  5. [5] HC Marbella International Hospital, Sociedad Española de Oncología (SEOM), Marbella, España
  6. [6] Hospital Universitario Bellvitge, Sociedad Española de Anatomía Patológica (SEAP), Hospitalet de Llobregat, España
  7. [7] Instituto Catalán de Oncología, Grupo de investigación en Oncología Aplicada, Instituto de Investigación Germans Trias i Pujol (IGTP), Sociedad Española de Oncología (SEOM), Badalona, España
  8. [8] Hospital Universitario Vall d’Hebron, Sociedad Española de Oncología (SEOM), Barcelona, España
  9. [9] Hospital Universitario Vall d’Hebron, Sociedad Española de Anatomía Patológica (SEAP), Barcelona, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 10 (October), 2022, págs. 1890-1902
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein–Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.